Thrombotic and bleeding complications in four subpopulations of patients with essential thrombocythemia defined by c-Mpl protein expression and PRV-1 mRNA levels.

Philipp L Goerttler(University of Freiburg), Heike L. Pahl(University Medical Center Freiburg), Jerry L. Spivak(Johns Hopkins University), Peter Johansson(Linköping University), Björn Andréasson(NU Hospital Group), Alison R. Moliterno(Johns Hopkins University), Jack Kutti(Sahlgrenska University Hospital), Roberto Marchioli(IQVIA (United Kingdom)), E März(University Hospital Ulm)
PubMed
June 1, 2005
Cited by 13

Related Papers

Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs
|Journal of Clinical Oncology|2012|461
The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 patients
|Blood|2011|340
Treatment-Related Risk Factors for Transformation to Acute Myeloid Leukemia and Myelodysplastic Syndromes in Myeloproliferative Neoplasms
|Journal of Clinical Oncology|2011|244
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study
|The Lancet|2023|194
MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis
|Blood|2014|153